Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells

Clinical and Experimental Metastasis

Volumn 29, Issue 2, 2012, Pages 133-142

  Rice, Lori ^a   Lepler, Sharon ^a   Pampo, Christina ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Dasatinib; Endothelial cells; Metastasis; Prostate cancer; SRC

Indexed keywords

DASATINIB; FOCAL ADHESION KINASE 1; PAXILLIN; PROTEIN KINASE B; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; FLUORESCENCE MICROSCOPY; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES;

EID: 84857156986     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9436-2     Document Type: Article

References (32)

1. J Sleeman PS Steeg 2010 Cancer metastasis as a therapeutic target Eur J Cancer 46 7 1177 1180 20307970 10.1016/j.ejca.2010.02.039 1:CAS:528: DC%2BC3cXkvFKqsbc%3D
2. D Santini S Galluzzo A Zoccoli F Pantano ME Fratto B Vincenzi L Lombardi C Gucciardino N Silvestris E Riva S Rizzo A Russo E Maiello G Colucci G Tonini 2010 New molecular targets in bone metastases Cancer Treat Rev 36S3 S6 S10 10.1016/S0305-7372(10)70013-X
3. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics CA Cancer J Clin 60 5 277 300 20610543 10.3322/caac.20073
4. George D, Moul JW (2011) Emerging treatment options for patients with castration-resistant prostate cancer. Prostate (in press)
5. EL Mayer IE Krop 2010 Advances in targeting SRC in the treatment of breast cancer and other solid malignancies Clin Cancer Res 16 14 3526 3532 20634194 10.1158/1078-0432.CCR-09-1834 1:CAS:528:DC%2BC3cXovVansLg%3D (Review)
6. A Aleshin RS Finn 2010 SRC: a century of science brought to the clinic Neoplasia 12 8 599 607 20689754 1:CAS:528:DC%2BC3cXpvVClsrs%3D (Review)
7. F Saad A Lipton 2010 SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer Cancer Treat Rev 36 2 177 184 20015594 10.1016/j.ctrv.2009.11.005 1:CAS:528:DC%2BC3cXjtFyhsb8%3D (Review)
8. MS Ahluwalia J Groot WM Liu CL Gladson 2010 Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies Cancer Lett 298 2 139 149 20947248 10.1016/j.canlet.2010.08.014 1:CAS:528:DC%2BC3cXhtlSgt7nI
9. RS Finn J Dering C Ginther CA Wilson P Glaspy N Tchekmedyian DJ Slamon 2007 Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 3 319 326 17268817 10.1007/s10549-006-9463-x 1:CAS:528:DC%2BD2sXhtFSlsr3N (Pubitemid 47596452)
10. J Araujo C Logothetis 2010 Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors Cancer Treat Rev 36 6 492 500 20226597 10.1016/j.ctrv.2010.02.015 1:CAS:528:DC%2BC3cXhtFWqsrrK (Review)
11. GE Konecny R Glas J Dering K Manivong J Qi RS Finn GR Yang KL Hong C Ginther B Winterhoff G Gao J Brugge DJ Slamon 2009 Activity of the multikinase inhibitor dasatinib against ovarian cancer cells Br J Cancer 101 10 1699 1708 19861960 10.1038/sj.bjc.6605381 1:CAS:528:DC%2BD1MXhtl2hs7rO
12. Z Guo B Dai T Jiang K Xu Y Xie O Kim I Nesheiwat X Kong J Melamed VD Handratta VC Njar AM Brodie LR Yu TD Veenstra H Chen Y Qiu 2006 Regulation of androgen receptor activity by tyrosine phosphorylation Cancer Cell 10 4 309 319 17045208 10.1016/j.ccr.2006.08.021 1:CAS:528:DC%2BD28XhtFCgsbjI (Pubitemid 44512189)
13. MD Galsky NJ Vogelzang 2010 Docetaxel-based combination therapy for castration-resistant prostate cancer Ann Oncol 21 11 2135 2144 20351071 10.1093/annonc/mdq050 1:STN:280:DC%2BC3cbhtl2htg%3D%3D
14. SI Park J Zhang KA Phillips JC Araujo AM Najjar AY Volgin JG Gelovani SJ Kim Z Wang GE Gallick 2008 Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model Cancer Res 68 9 3323 3333 18451159 10.1158/0008-5472.CAN-07-2997 1:CAS:528:DC%2BD1cXltlSlsL4%3D
15. T Koreckij H Nguyen LG Brown EY Yu RL Vessella E Corey 2009 Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis Br J Cancer 101 2 263 268 19603032 10.1038/sj.bjc.6605178 1:CAS:528:DC%2BD1MXoslOmtLc%3D
16. A Yano S Tsutsumi S Soga MJ Lee J Trepel H Osada L Neckers 2008 Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone Proc Natl Acad Sci USA 105 40 15541 15546 18840695 10.1073/pnas.0805354105 1:CAS:528:DC%2BD1cXht1Gnt73F
17. W Liang M Kujawski J Wu J Lu A Herrmann S Loera Y Yen H Lee W Wen R Jove 2010 Antitumor activity of targeting Src kinases in endothelial and myeloid cell compartments of the tumor microenvironment Clin Cancer Res 15 3 924 935 10.1158/1078-0432.CCR-09-1486
18. A Chung N Ferrara 2010 Targeting the tumor microenvironment with Src kinase inhibition Clin Cancer Res 16 3 775 777 20103657 10.1158/1078-0432.CCR- 09-3081 1:CAS:528:DC%2BC3cXhs1aru7k%3D
19. EY Yu G Wilding E Posadas M Gross S Culine C Massard MJ Morris G Hudes F Calabrò S Cheng GC Trudel P Paliwal CN Sternberg 2009 Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 23 7421 7428 19920114 10.1158/1078-0432.CCR-09-1691 1:CAS:528:DC%2BD1MXhsFSnu7vO
20. O Tatarov TJ Mitchell M Seywright HY Leung VG Brunton J Edwards 2009 SRC family kinase activity is up-regulated in hormone-refractory prostate cancer Clin Cancer Res 15 10 3540 3549 19447874 10.1158/1078-0432.CCR-08-1857 1:CAS:528:DC%2BD1MXmtVKlsrc%3D
21. S Kopetz AN Shah GE Gallick 2007 Src continues aging: current and future clinical directions Clin Cancer Res 13 7232 7236 18094400 10.1158/1078-0432.CCR- 07-1902 1:CAS:528:DC%2BD2sXhsVCktr%2FO
22. LC Kim L Song EB Haura 2009 Src kinases as therapeutic targets for cancer Nat Rev Clin Oncol 6 10 587 595 19787002 10.1038/nrclinonc.2009.129
23. Sen B, Johnson FM (2011) Regulation of Src family kinases in human cancers. J Signal Transduct 2011:865819
24. D Caccia F Miccichè G Cassinelli P Mondellini P Casalini I Bongarzone 2010 Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line Mol Cancer 9 278 20955590 10.1186/1476-4598-9-278
25. AJ Eustace J Crown M Clynes N O'Donovan 2008 Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines J Transl Med 6 53 18823558 10.1186/1479-5876-6-53
26. A Serrels IR Macpherson TR Evans FY Lee EA Clark OJ Sansom GH Ashton MC Frame VG Brunton 2006 Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib Ser Mol Cancer Ther 5 12 3014 3022 10.1158/1535-7163.MCT-06-0382 1:CAS:528:DC%2BD28Xhtlagsb3L (Pubitemid 46092042)
27. FM Johnson B Saigal M Talpaz NJ Donato 2005 Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells Clin Cancer Res 11 19 Pt 1 6924 6932 16203784 10.1158/1078-0432. CCR-05-0757 1:CAS:528:DC%2BD2MXhtVKiurvN (Pubitemid 41428750)
28. B Sen SH Peng B Saigal MD Williams FM Johnson 2010 Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer Clin Cancer Res 17 3 514 524 21106725 10.1158/1078-0432.CCR-10-1617
29. NS Nagaraj JJ Smith F Revetta MK Washington NB Merchant 2010 Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis Mol Cancer Ther 9 2322 2332 20682659 10.1158/1535-7163.MCT-09-1212 1:CAS:528:DC%2BC3cXpvVOjsbY%3D
30. MV Yezhelyev G Koehl M Guba T Brabletz KW Jauch A Ryan A Barge T Green M Fennell M Bruns 2004 Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice Clin Cancer Res 10 23 8028 8036 15585638 10.1158/1078-0432.CCR-04-0621 1:CAS:528:DC%2BD2cXhtVCrs7rE (Pubitemid 39587544)
31. Y Dai DW Siemann 2010 BMS-777607, a small molecule Met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro Mol Cancer Ther 9 1554 1561 20515943 10.1158/1535-7163.MCT- 10-0359 1:CAS:528:DC%2BC3cXntFGgsLs%3D
32. JG Trevino JM Summy DP Lesslie NU Parikh DS Hong FY Lee NJ Donato JL Abbruzzese CH Baker GE Gallick 2006 Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model Am J Pathol 168 3 962 972 16507911 10.2353/ajpath.2006.050570 1:CAS:528:DC%2BD28XislGguro%3D (Pubitemid 43327748)